Guggenheim Increases ICON Public (NASDAQ:ICLR) Price Target to $262.00

ICON Public (NASDAQ:ICLR – Get Rating) had its price target lifted by Guggenheim from $255.00 to $262.00 in a research report report published on Friday morning, The Fly reports. The brokerage currently has a buy rating on the medical research company’s stock.

Several other analysts have also recently issued reports on ICLR. StockNews.com upgraded ICON Public from a sell rating to a hold rating in a research note on Tuesday, October 11th. Deutsche Bank Aktiengesellschaft cut their price objective on ICON Public from $295.00 to $280.00 in a research note on Tuesday, October 18th. TheStreet upgraded ICON Public from a c rating to a b- rating in a research note on Thursday, November 3rd. Mizuho cut their price objective on ICON Public from $272.00 to $250.00 and set a buy rating on the stock in a research note on Thursday, November 10th. Finally, Barclays upgraded ICON Public from an equal weight rating to an overweight rating and upped their price objective for the company from $215.00 to $260.00 in a research note on Friday, January 13th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus price target of $264.70.

ICON Public Trading Up 0.5 %

NASDAQ:ICLR opened at $231.42 on Friday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.16 and a current ratio of 1.16. ICON Public has a one year low of $171.43 and a one year high of $279.80. The business’s 50-day simple moving average is $207.56 and its 200 day simple moving average is $208.48. The stock has a market cap of $18.84 billion, a price-to-earnings ratio of 41.10, a price-to-earnings-growth ratio of 1.37 and a beta of 1.04.

ICON Public (NASDAQ:ICLR – Get Rating) last released its quarterly earnings results on Wednesday, November 2nd. The medical research company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.76 by $0.08. ICON Public had a return on equity of 10.75% and a net margin of 6.06%. The business had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.94 billion. As a group, sell-side analysts predict that ICON Public will post 10.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ICON Public

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. TimesSquare Capital Management LLC grew its holdings in ICON Public by 9.2% in the 2nd quarter. TimesSquare Capital Management LLC now owns 272,800 shares of the medical research company’s stock worth $59,116,000 after buying an additional 22,900 shares in the last quarter. Todd Asset Management LLC grew its holdings in ICON Public by 21.0% in the 3rd quarter. Todd Asset Management LLC now owns 139,542 shares of the medical research company’s stock worth $25,644,000 after buying an additional 24,223 shares in the last quarter. Captrust Financial Advisors grew its holdings in ICON Public by 4.8% in the 2nd quarter. Captrust Financial Advisors now owns 28,338 shares of the medical research company’s stock worth $6,141,000 after buying an additional 1,296 shares in the last quarter. Liontrust Investment Partners LLP bought a new position in ICON Public in the 2nd quarter worth approximately $5,357,000. Finally, Russell Investments Group Ltd. grew its holdings in ICON Public by 1.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 22,379 shares of the medical research company’s stock worth $4,111,000 after buying an additional 344 shares in the last quarter. 92.32% of the stock is owned by institutional investors.

ICON Public Company Profile

(Get Rating)

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.